🇺🇸 FDA

Intelligence · Clinical Pipeline

Oncology · Phase II

Oncology programs at Phase II — ClinicalTrials.gov pipeline intelligence.

Programs
2,640

Quick answer

Oncology Phase II programs: NovaPharmaNews indexes 2,640 matching clinical development programs from ClinicalTrials.gov with sponsor, modality, and NCT cross-links.

Top sponsors

Page 45 of 55

  1. Stivarga 40 mg film-coated tablets, Tevimbra 100 mg concentrate for solution for infusion, OMTX705

    Lacuna Pharma Pty Ltd

    Advanced/metastatic colorectal cancer

    phase 2 small molecule active

    1 trial

  2. Streptococcus salivarius K12

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Head and Neck Squamous Cell Carcinoma

    phase 2 small molecule completed

    1 trial

  3. Study evaluating the efficacy of the treatment after targeting PD-L1 and TIGIT in tumors with tertiary lymphoid structures

    The George Institute

    Adult patients with a histologically confirmed TLS-positive advanced or metastatic NSCLC naïve from systemic treatment or previously treated with chemotherapy and PD1/PDL1 antagonist, and not having previously been treated with CD137 agonists or investigational immune checkpoint blockade therapies, including (but not limited) anti-TIGIT, anti-LAG3. Patients must have adequate organ function with a performance status (WHO 0-1; ECOG 0-1). Patients must not have active or history of autoimmune disease or immune deficiency. The pregnant or breastfeeding women will be excluded. Other eligibility criteria are described in the related section of the protocol.

    phase 2 other active

    1 trial

  4. Study of IBI3009 alone or in combination with other therapies for extensive-stage small cell lung cancer

    Talion

    Extensive-Stage Small Cell Lung Cancer

    phase 2 other active

    1 trial

  5. Sunvozertinib

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Potentially Resectable EGFR Exon 20 Insertion Non-Small Cell Lung Cancer

    phase 2 small molecule active

    1 trial

  6. Sunvozertinib, Sunvozertinib

    Lacuna Pharma Pty Ltd

    Non-Small Cell Lung Cancer

    phase 2 small molecule active

    1 trial

  7. Surufatinib

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Biliary Tract Cancer

    phase 2 small molecule active

    1 trial

  8. Surufatinib + Serplulimab+Albumin-paclitaxel + Gemcitabine

    Sun Yat-sen University

    Locally Advanced Pancreatic Cancer

    phase 2 small molecule active

    1 trial

  9. Surzebiclimab

    BeiGene

    Locally Advanced or Metastatic Solid Tumors for Phase 1, Dose Escalation and Phase 2 Safety Lead-in

    phase 2 small molecule completed

    1 trial

  10. Surzebiclimab

    BEONE MEDICINES AUS PTY LTD

    Locally Advanced or Metastatic Solid Tumors for Phase 1, Dose Escalation and Phase 2 Safety Lead-in

    phase 2 small molecule completed

    1 trial

  11. Systemic chemotherapy (FOLFIRI)

    The First People's Hospital of Lianyungang

    Rectum Cancer

    phase 2 small molecule completed

    1 trial

  12. TACE and HAIC Combined With Regorafenib

    The First People's Hospital of Lianyungang

    Liver Metastasis Colon Cancer

    phase 2 other completed

    1 trial

  13. TAGRISSO 80 mg film-coated tablets, TAGRISSO 40 mg film-coated tablets

    AstraZeneca AB

    Non-Small Cell Lung Cancer

    phase 2 small molecule active

    1 trial

  14. TAGRISSO 80 mg film-coated tablets, TAGRISSO 40 mg film-coated tablets, Tepotinib

    Merck Sharp and Dohme

    Lung Cancer

    phase 2 small molecule active

    1 trial

  15. TAK-007

    Takeda

    Relapsed or Refractory (r/r) B-cell Non-Hodgkin Lymphoma (NHL)

    phase 2 mab active

    1 trial

  16. TAK-186

    Takeda

    Squamous Cell Cancer of Head and Neck (SCCHN)

    phase 2 small molecule terminated

    1 trial

  17. TAK-188

    Takeda

    Advanced or Metastatic Solid Tumors

    phase 2 small molecule active

    1 trial

  18. TAK-280

    Takeda

    Unresectable Locally Advanced or Metastatic Cancer

    phase 2 small molecule terminated

    1 trial

  19. TAK-280, SILTUXIMAB, TOCILIZUMAB, TOCILIZUMAB, SILTUXIMAB, TOCILIZUMAB

    Takeda

    Unresectable Locally Advanced or Metastatic Cancer

    phase 2 small molecule active

    1 trial

  20. TAK-385

    Takeda

    Prostate Cancer

    phase 2 small molecule completed

    1 trial

  21. TAK-500

    Takeda

    Pancreatic Cancer

    phase 2 small molecule terminated

    1 trial

  22. TAK-505

    Takeda

    Malignant Solid Tumors

    phase 2 small molecule active

    1 trial

  23. TAK-700

    Takeda

    Prostate Cancer

    phase 2 small molecule completed

    1 trial

  24. TAK-788

    Takeda

    Non-Small Cell Lung Cancer (NSCLC)

    phase 2 small molecule terminated

    1 trial

  25. TAK-788

    Takeda

    Carcinoma, Non-Small-Cell Lung

    phase 2 small molecule active

    1 trial

  26. TAK-853

    Takeda

    Ovarian Cancer

    phase 2 small molecule active

    1 trial

  27. TAK-931

    Takeda

    Metastatic Pancreatic Cancer

    phase 2 small molecule completed

    1 trial

  28. TAK-981

    Takeda

    Neoplasms

    phase 2 small molecule terminated

    1 trial

  29. TAK-981

    Takeda

    Advanced or Metastatic Solid Tumors

    phase 2 small molecule completed

    1 trial

  30. TAK-981

    Takeda

    Lymphoma, Non-Hodgkin

    phase 2 small molecule terminated

    1 trial

  31. TAK228

    Takeda

    Lymphoma

    phase 2 small molecule terminated

    1 trial

  32. TAMBICICLIB 100 mg/10 mL, Solution for Injection, AZACITIDINE , TAMBICICLIB 100 mg/20 mL, Solution for Injection, VENETOCLAX

    Istituto Gentili S.r.l.

    Acute myeloid leukemia

    phase 2 small molecule active

    1 trial

  33. TARA-002

    Protara Therapeutics

    Non-muscle Invasive Bladder Cancer

    phase 2 mab active

    3 trials

  34. TAS-120

    Taiho Pharma Netherlands B.V.

    Advanced Cholangiocarcinoma

    phase 2 small molecule active

    1 trial

  35. TAXOTERE 20 mg/1 ml concentrate for solution for infusion, Budigalimab, Livmoniplimab, Paclitaxel 6 mg/mL concentrate for solution for infusion, Gemcitabine 38 mg/mL concentrate for solution for infusion

    AbbVie Deutschland GmbH & Co. KG

    Urothelial Carcinoma, Metastatic Urothelial Carcinoma

    phase 2 small molecule active

    1 trial

  36. TAZEMETOSTAT, IMFINZI 50 mg/mL concentrate for solution for infusion.

    The George Institute

    Adult participants with metastatic or unresectable locally advanced solid tumors.

    phase 2 small molecule active

    1 trial

  37. TD001

    Wuhan Createrna Science and Technology Co., Ltd

    Metastatic castration-resistant prostate cancer

    phase 2 small molecule active

    1 trial

  38. TEBENTAFUSP

    Fondazione Telethon ETS

    metastatic uveal melanoma HLA A*02:01 positive

    phase 2 small molecule active

    1 trial

  39. TEDOPI, LIBTAYO 350 mg concentrate for solution for infusion., Armisarte 25 mg/ml concentrate for solution for infusion

    Fondazione Telethon ETS

    NSCLC non-small cell lung cancer

    phase 2 small molecule active

    1 trial

  40. TEMOZOLOMIDE

    Istituto Gentili S.r.l.

    Patients with well differentiated neuroendocrine neoplasia (NENs) not eligible for active antitumoral treatments due to their clinical conditions.

    phase 2 small molecule active

    1 trial

  41. TEMOZOLOMIDE , IRINOTECAN

    Fondazione Telethon ETS

    Stage II (pT4)/III colorectal cancer with positive circulating tumor DNA (ctDNA) after oxaliplatin-based adjuvant chemotherapy

    phase 2 small molecule active

    1 trial

  42. TEMOZOLOMIDE VIATRIS 5 mg, gélule, Capivasertib, TEMOZOLOMIDE VIATRIS 100 mg, gélule, VINORELBINE ACCORD 20 mg, capsule molle, Votubia 3 mg dispersible tablets, Bavencio 20 mg/mL concentrate for solution for infusion, Peposertib, INC280, Enasidenib Mesilate, Futibatinib, TEMOZOLOMIDE VIATRIS 20 mg, gélule, Capivasertib, VINORELBINE ACCORD 30 mg, capsule molle, INC280, Enasidenib Mesilate, Votubia 5 mg dispersible tablets, Votubia 2 mg dispersible tablets, Capivasertib

    The George Institute

    pediatric cancer

    phase 2 small molecule active

    1 trial

  43. TEMOZOLOMIDE, TEMOZOLOMIDE, CAPECITABINE

    Fondazione Telethon ETS

    locally advanced rectal cancer (LARC)

    phase 2 small molecule active

    1 trial

  44. TEMOZOLOMIDE, TEMOZOLOMIDE, TOCILIZUMAB, CALCIUM FOLINATE, CYCLOPHOSPHAMIDE, RITUXIMAB, Lisocabtagene maraleucel, TEMOZOLOMIDE, PROCARBAZINE, FLUDARABINE, METHOTREXATE, TEMOZOLOMIDE, CALCIUM FOLINATE

    Bristol-Myers Squibb Australia Pty Ltd

    Primary Central Nervous System Lymphoma

    phase 2 small molecule active

    1 trial

  45. TGR-1202

    TG THERAPEUTICS, INC.

    Follicular Lymphoma

    phase 2 small molecule terminated

    1 trial

  46. TGR-1202

    TG THERAPEUTICS, INC.

    Chronic Lymphocytic Leukemia

    phase 2 small molecule terminated

    1 trial

  47. TGRX-326

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Non-small Cell Lung Cancer

    phase 2 small molecule active

    1 trial

  48. THOR-707

    Sanofi Pasteur

    Malignant Melanoma

    phase 2 small molecule terminated

    1 trial

Frequently asked questions

How many oncology Phase II programs exist?

2,640 programs match both the therapeutic area and stage filters in our published index.

Data attribution: Data sources · All pipeline programs

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.